Venture Leaders Life Sciences 2018 - Meet Daniela Marino of CUTISS
scroll south
In exactly 10 days, Daniela Marino, CUTISS CEO and co-founder, will fly to Boston for a deep dive into the local Life Sciences industry. A unique opportunity to get exposure for her Biotech startup. Daniela shared with us her motivation for applying to the program.
Who are you and what is CUTISS?I am Daniela Marino, co-founder and CEO of CUTISS AG, a University of Zurich spin-off startup. At CUTISS we develop personalized tissue engineered skin therapy for patients with skin defects. CUTISS’ first in line product, denovoSkin, has been developed in the last 15 years and it is now in phase IIB clinical trials.
What attracted you to Boston as your business development destination?
Boston is the entry door to the American Life Sciences world. The FDA (Food and Drug Administration - American agency) has already granted denovoSkin with Orphan Drug Designation for the treatment of burns, so the USA will be one of our first markets.
What do you hope to achieve from the trip?
To meet US investors, startups, and to better understand regulatory and market entrance dynamics.
What does the Venture Leaders Life Sciences mean for you?
It is a perfect platform for us to make the first steps over the ocean.
What is pushing you towards international expansion?
Patients are in need for a real solution worldwide.
What do you foresee as the largest hurdles towards expansion
into the Boston area?
Establishing a solid and long-lasting network.
What makes you most nervous or excited about the trip?
Nothing makes me nervous, I am counting minutes until this adventure starts!
Follow the Venture Leaders Life Sciences roadshow on Twitter and Facebook using the hashtag #vleadearsLifeScience.
Venture Leaders Life Sciences is co-organized by Venturelab and swissnex Boston, and supported by Kellerhals Carrard, digitalswitzerland, Canton de Vaud, Canton of Zurich, Wyss Foundation, EY entreprenenur of the year, EPF Lausanne, ETH Zurich, Paul Scherrer Institut and University of Zurich.
